For Refractory CLL, Venetoclax's (ABT-199's) C... - CLL Support

CLL Support

22,512 members38,667 posts

For Refractory CLL, Venetoclax's (ABT-199's) Complete Response Rate Is Tops

AussieNeil profile image
AussieNeilAdministrator
0 Replies

"The combination therapy of the novel anti-BCL-2 drug venetoclax (formerly ABT-199/GDC-0199, AbbVie, Genentech) and rituximab shows encouraging results in the treatment of refractory chronic lymphocytic leukemia (CLL), according to early results from an ongoing clinical trial.

The complete response rate seen with venetoclax is especially notable, said lead investigator Andrew W. Roberts, MBBS, PhD, from the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, in Australia."

medscape.com/viewarticle/84...

With thanks to Brian Koffman for bringing this to my attention.

Neil

Photo: Meadow Argus butterfly - with thanks as usual to Jay for identification

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Venetoclax(ABT-199)/rituximab achieved an Overall Rate of Response of 88%

Options (free to join) capsule update on... Venetoclax (ABT-199)Plus Rituximab Well Tolerated...

Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients

breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the path...

CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)

-on-the-fda-approval-of-liso-cel-in-relapsed-refractory-cll-sll

Results of Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory CLL

treatment-naïve patients and 88% in relapsed or refractory patients.\\" A short report here:...

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease.

residual disease. I would welcome the chance to add venetoclax to my treatment as in this study...